Innoviva, Inc. INVA · Stock Open Innoviva, Inc. in new tab
Innoviva, Inc. Analysis (INVA)
Is Innoviva, Inc. a good investment? Innoviva, Inc. (INVA) is currently trading at 20.77 USD. Market analysts have a consensus price target of 35.50 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 3.39. This relatively low multiple may signal that Innoviva, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Innoviva, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is 2.21.
Investor FAQ
Does Innoviva, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Innoviva, Inc.?
Innoviva, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 6.26.
Company Profile
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Year | Total Dividends |
|---|---|
| ▸2015 |
0.75 USD
|
| Sept. 30, 2015 | 0.2500 |
| June 30, 2015 | 0.2500 |
| March 31, 2015 | 0.2500 |
| ▸2014 |
0.50 USD
|
| Dec. 23, 2014 | 0.2500 |
| Sept. 18, 2014 | 0.2500 |
| Split Date | Split Ratio to 1 |
|---|---|
| June 3, 2014 | 1.240000 |
Community Discussion